image copyrightGetty Images
Michelle Roberts Digital Health Editor-in-Chief
A clinical trial of a drug to treat pancreatic cancer, one of the most lethal and difficult to treat cancers, has recently confirmed cases in which tumors completely disappeared. Experts are calling this the breakthrough in decades.
In early clinical trials of the new drug Daraxone Lasib, one in 12 people who took the drug daily in combination with chemotherapy had undetectable cancer.
Additionally, in nearly all of the 61 trial participants who were diagnosed with advanced pancreatic cancer that had spread to other parts of the body, their tumors stopped growing.
However, doctors stress that it is not yet known how long the drug can slow disease progression, so it should not be considered a cure.
incredible results
Cancer Research UK, a British cancer research group, described the results as "the biggest breakthrough for pancreatic cancer patients in decades".
Dr Sam Godfrey, from the charity, told BBC News the findings were fantastic and exciting. ``This new drug has found a way to make medicine effective for a disease that cannot be cured.''
"We are finally starting to see progress in pancreatic cancer treatment, which has been stagnant for a long time."
Pancreatic cancer is extremely difficult to treat and has the lowest survival rate of any common cancer in the UK.
Although chemotherapy can shrink tumors slightly, pancreatic cancer tumors often grow back.
If the cancer is at an advanced stage, most patients only live for a few months, but many do not live for several years.
Doctors hope the new drug will give patients a little more time to live, even if it won't completely stop cancer.
The clinical trial followed participants for an average of one and a half years. Some patients did not experience cancer recurrence during this period.
Longer-term studies are needed to determine whether participants' cancer goes into remission and how long their remission lasts.
This clinical trial yielded the following results.
- Tumor growth stopped in 90% of participating patients
- Tumors shrunk or disappeared in over 60% of patients
- In about 8% of patients, or 1 in 12, the tumor is no longer detected on CT scans.
Survive longer
Dr. Eun-ki Park from Memorial Sloan Kettering Cancer Center in the US, who was involved in the clinical trial, said the results so far have been very promising.
"We are beginning to see that tumor response rates are not only improving, but also broader, and that the duration of disease control is nearly doubling, which may ultimately lead to longer survival times," Dr. Park explained.
Dalaxone lasib is a KRAS inhibitor already approved in the United States. The drug works by binding to and inhibiting a specific genetic mutation called RAS, which is found in most pancreatic cancers and promotes tumor growth.
Similar gene mutations are found in dozens of other cancers, including lung and ovarian cancers, so the drug could be effective for many other cancer patients.
"We hope that the successes seen in early clinical trials with pancreatic cancer will translate to other cancers," Dr. Godfrey said.
However, he noted that longer clinical trials and their results are essential. "Cancer can come back. Even if tests don't show any signs of cancer, it doesn't necessarily mean the cancer is cured until more time has passed."
Professor Elena Garalda, head of the European Organization for Research and Treatment of Cancer (EORTC), said: "These results are very exciting because they show that the combination therapy has the potential to significantly improve overall survival for patients and can also shorten the time it takes for tumors to start growing again." The results of this research will be announced by EORTC.
According to Cancer Research UK, 11,500 people are diagnosed with pancreatic cancer each year in the UK and around 10,200 die from it.
Actor Alan Rickman passed away in 2016, just five months after being diagnosed.
Symptoms include jaundice, itchy skin, dark urine, pale stools, unexplained weight loss, fatigue, and high fever.
(English article: Massive hope for pancreatic cancer pill after trial saw tumours vanish)




